Sunday, November 15, 2026
20.1 C
Bengaluru

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS
August 10, 2026: Regulatory Authorisation — The UK Medicines and Healthcare products Regulatory Agency (MHRA) officially approved/authorised orforglipron (Foundayo).
August 24, 2026: Commercial Launch — Eli Lilly officially launched the drug in the UK, making it available to patients via private prescriptions.

The Real GLP-1 War in India: When the Molecule Becomes a Commodity, What Becomes the Moat?

The GLP-1 revolution has entered a new phase: competition now shifts from the molecule to everything around it. Eli Lilly's Foundayo (orforglipron) launched in the UK, making Britain the first European market for Lilly's once-daily oral GLP-1. Unlike oral semaglutide, orforglipron is a non-peptide small molecule: no food/water restrictions, no sterile injection devices, no complex fill-finish, and no refrigeration. For India, where Novo Nordisk's core semaglutide patent expired on March 20, 2026, the strategic stakes are clear: competitors must now win on distribution, adherence, trust, and ecosystem support, not just on the molecule. As the molecule becomes a commodity, competitive advantage shifts to everything surrounding it.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img